Biotech and Pharma Industry News | BioPharma Dive
WEBFTC sues major pharmacy benefit managers over insulin prices. The agency brought action against Caremark, Express Scripts and Optum Rx Friday, and warned that all drug manufacturers “should be on notice” as well. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Radiopharmaceuticals for cancer: Making radiation precise
WEBAug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
Novartis wins FDA OK for radiopharmaceutical drug, cashing in on ...
WEBMar 24, 2022 · Novartis has won Food and Drug Administration approval to sell a radiopharmaceutical designed to treat a form of advanced prostate cancer in a key step forward for an area of research the Swiss drugmaker has prioritized in recent years. The FDA cleared the infusion, known as Pluvicto, based on study results showing it could cut …
Biohaven starts life as new company following Pfizer buyout
WEBOct 5, 2022 · On Tuesday, Biohaven Ltd. officially launched as a newly independent company, spun out of its former parent as part of Pfizer’s $11.6 billion acquisition, which closed on Oct. 3. Led by the same CEO, Vlad Coric, and publicly traded under the same stock ticker, the new Biohaven retains a pipeline of experimental medicines for a range …
ADC startup ProfoundBio, led by Seagen veterans, raises $112M
WEBFeb 13, 2024 · Love Employee via Getty Images. A Seattle biotechnology startup formed by veterans of Seagen has raised $112 million to develop a pipeline of antibody-drug conjugates, the targeted cancer medicines for which Seagen was known. Funding for the startup, ProfoundBio, was led by Ally Bridge Group and also involved several …
J&J spinoff Kenvue raises $3.8 billion in year’s largest IPO
WEBMay 4, 2023 · Dive Insight: The $3.8 billion haul represents the largest IPO since electric car marker Rivian raised $11.9 billion in November 2021 and could boost the struggling market for public offerings in the U.S.. With the Kenvue spinoff and an offering from the biotechnology company Acelyrin due to price Thursday night, IPO proceeds this year are …
Pfizer wins FDA approval for its $7B colitis drug
WEBOct 13, 2023 · Pfizer set a list price of $6,164 for a 30-day supply of the once-daily pill, or about $75,000 a year. That is in line with oral treatments like Pfizer’s own Xeljanz and AbbVie’s Rinvoq, and less than the $100,000 annual price Bristol Myers set for Zeposia. Zeposia was first approved as a multiple sclerosis drug, allowing it to command a ...
Pharma News | BioPharma Dive
WEBSep 27, 2024 · Novo sinks on obesity drug results; Sanofi reveals anticipated MS data. A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged. By BioPharma Dive staff •Sept. 20, 2024.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high …
10 clinical trials to watch in the second half of 2022
WEBJul 5, 2022 · The second half of the year could bring similarly important results from clinical trials testing drugs for Alzheimer’s disease, cancer and vision loss. Positive data, if it comes, might give biotech a needed boost. Here are 10 trials to watch: Companies: Eisai, Biogen. Disease: Alzheimer's. Treatment type: